Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26300
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVetro, Annalisa-
dc.contributor.authorNielsen, Hang N-
dc.contributor.authorHolm, Rikke-
dc.contributor.authorHevner, Robert F-
dc.contributor.authorParrini, Elena-
dc.contributor.authorPowis, Zoe-
dc.contributor.authorMøller, Rikke S-
dc.contributor.authorBellan, Cristina-
dc.contributor.authorSimonati, Alessandro-
dc.contributor.authorLesca, Gaétan-
dc.contributor.authorHelbig, Katherine L-
dc.contributor.authorPalmer, Elizabeth E-
dc.contributor.authorMei, Davide-
dc.contributor.authorBallardini, Elisa-
dc.contributor.authorHaeringen, Arie Van-
dc.contributor.authorSyrbe, Steffen-
dc.contributor.authorLeuzzi, Vincenzo-
dc.contributor.authorCioni, Giovanni-
dc.contributor.authorCurry, Cynthia J-
dc.contributor.authorCostain, Gregory-
dc.contributor.authorSantucci, Margherita-
dc.contributor.authorChong, Karen-
dc.contributor.authorMancini, Grazia M S-
dc.contributor.authorClayton-Smith, Jill-
dc.contributor.authorA-Collaborators, Atp A/-
dc.contributor.authorBigoni, Stefania-
dc.contributor.authorScheffer, Ingrid E-
dc.contributor.authorDobyns, William B-
dc.contributor.authorVilsen, Bente-
dc.contributor.authorGuerrini, Renzo-
dc.date2021-04-21-
dc.date.accessioned2021-04-26T22:38:37Z-
dc.date.available2021-04-26T22:38:37Z-
dc.date.issued2021-06-22-
dc.identifier.citationBrain : a journal of neurology 2021; 144(5): 1435-1450en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/26300-
dc.description.abstractConstitutional heterozygous mutations of ATP1A2 and ATP1A3, encoding for two distinct isoforms of the Na+/K+-ATPase (NKA) alpha-subunit, have been associated with familial hemiplegic migraine (ATP1A2), alternating hemiplegia of childhood (ATP1A2/A3), rapid-onset dystonia-parkinsonism, cerebellar ataxia-areflexia-progressive optic atrophy, and relapsing encephalopathy with cerebellar ataxia (all ATP1A3). A few reports have described single individuals with heterozygous mutations of ATP1A2/A3 associated with severe childhood epilepsies. Early lethal hydrops fetalis, arthrogryposis, microcephaly, and polymicrogyria have been associated with homozygous truncating mutations in ATP1A2. We investigated the genetic causes of developmental and epileptic encephalopathies variably associated with malformations of cortical development in a large cohort and identified 22 patients with de novo or inherited heterozygous ATP1A2/A3 mutations. We characterized clinical, neuroimaging and neuropathological findings, performed in silico and in vitro assays of the mutations' effects on the NKA-pump function, and studied genotype-phenotype correlations. Twenty-two patients harboured 19 distinct heterozygous mutations of ATP1A2 (six patients, five mutations) and ATP1A3 (16 patients, 14 mutations, including a mosaic individual). Polymicrogyria occurred in 10 (45%) patients, showing a mainly bilateral perisylvian pattern. Most patients manifested early, often neonatal, onset seizures with a multifocal or migrating pattern. A distinctive, 'profound' phenotype, featuring polymicrogyria or progressive brain atrophy and epilepsy, resulted in early lethality in seven patients (32%). In silico evaluation predicted all mutations to be detrimental. We tested 14 mutations in transfected COS-1 cells and demonstrated impaired NKA-pump activity, consistent with severe loss of function. Genotype-phenotype analysis suggested a link between the most severe phenotypes and lack of COS-1 cell survival, and also revealed a wide continuum of severity distributed across mutations that variably impair NKA-pump activity. We performed neuropathological analysis of the whole brain in two individuals with polymicrogyria respectively related to a heterozygous ATP1A3 mutation and a homozygous ATP1A2 mutation and found close similarities with findings suggesting a mainly neural pathogenesis, compounded by vascular and leptomeningeal abnormalities. Combining our report with other studies, we estimate that ∼5% of mutations in ATP1A2 and 12% in ATP1A3 can be associated with the severe and novel phenotypes that we describe here. Notably, a few of these mutations were associated with more than one phenotype. These findings assign novel, 'profound' and early lethal phenotypes of developmental and epileptic encephalopathies and polymicrogyria to the phenotypic spectrum associated with heterozygous ATP1A2/A3 mutations and indicate that severely impaired NKA pump function can disrupt brain morphogenesis.en
dc.language.isoeng
dc.subjectATP1A2en
dc.subjectATP1A3en
dc.subjectNa+/K+-ATPase pumpen
dc.subjectdevelopmental and epileptic encephalopathyen
dc.subjectpolymicrogyriaen
dc.titleATP1A2- and ATP1A3-associated early profound epileptic encephalopathy and polymicrogyria.en
dc.typeJournal Articleen
dc.identifier.journaltitleBrain : a journal of neurologyen
dc.identifier.affiliationPediatric Neurology, Neurogenetics and Neurobiology Unit and Laboratories, Meyer Children's Hospital, University of Florence, Florence, Italyen
dc.identifier.affiliationSchool of Women's and Children's Health, University of New South Wales, Randwick, NSW, Australiaen
dc.identifier.affiliationCentre for Clinical Genetics, Sydney Children's Hospital, Randwick, NSW, Australiaen
dc.identifier.affiliationDepartment of Regional Health Services, University of Southern Denmark, Odense, Denmarken
dc.identifier.affiliationDepartment of Epilepsy Genetics and Personalized Medicine Danish Epilepsy Centre, Filadelfia, Denmarken
dc.identifier.affiliationDIBINEM, University of Bologna, Bologna, Italyen
dc.identifier.affiliationDepartment of Biomedicine, Aarhus University, DK-8000, Aarhus C, Denmarken
dc.identifier.affiliationChild Neuropsychiatry Unit, IRCCS, Institute of Neurological Sciences, Bellaria Hospital, Bologna, Italyen
dc.identifier.affiliationUniversity of Melbourne, and Royal Children's Hospital, Florey and Murdoch Institutes, Melbourne, Australiaen
dc.identifier.affiliationDepartment of Biomedicine, Aarhus University, DK-8000, Aarhus C, Denmarken
dc.identifier.affiliationDepartment of Pathology, University of California San Diego, San Diego, CA, USAen
dc.identifier.affiliationPediatric Neurology, Neurogenetics and Neurobiology Unit and Laboratories, Meyer Children's Hospital, University of Florence, Florence, Italyen
dc.identifier.affiliationAmbry Genetics, Aliso Viejo, CA, USAen
dc.identifier.affiliationDepartment of Neonatal Intensive Care Unit, Bolognini Hospital, ASST-Bergamo Est, Seriate, Italyen
dc.identifier.affiliationNeurology (Child Neurology and Neuropathology), Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italyen
dc.identifier.affiliationDepartment of Medical Genetics, Member of the ERN EpiCARE, University Hospital of Lyon, Lyon, Franceen
dc.identifier.affiliationDivision of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USAen
dc.identifier.affiliationPediatric Neurology, Neurogenetics and Neurobiology Unit and Laboratories, Meyer Children's Hospital, University of Florence, Florence, Italyen
dc.identifier.affiliationNeonatal Intensive Care Unit, Pediatric Section, Department of Medical Sciences, Ferrara University, Ferrara, Italyen
dc.identifier.affiliationDepartment of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlandsen
dc.identifier.affiliationDivision of Pediatric Epileptology, Centre for Paediatrics and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germanyen
dc.identifier.affiliationDepartment of Human Neuroscience, Unit of Child Neurology and Psychiatry, Sapienza University, Rome, Italyen
dc.identifier.affiliationDepartment of Developmental Neuroscience, IRCCS Fondazione Stella Maris, Pisa, Italyen
dc.identifier.affiliationGenetic Medicine, Department of Pediatrics, University of California, San Francisco/Fresno, CA, USAen
dc.identifier.affiliationDivision of Clinical and Metabolic Genetics, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canadaen
dc.identifier.affiliationThe Prenatal Diagnosis and Medical Genetics Program, Department of Obstetrics and Gynecology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canadaen
dc.identifier.affiliationDepartment of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlandsen
dc.identifier.affiliationManchester Centre for Genomic Medicine, University of Manchester, St Mary's Hospital, Manchester, UKen
dc.identifier.affiliationMedical Genetics Unit, Department of Mother and Child, Ferrara University Hospital, Ferrara, Italyen
dc.identifier.affiliationDepartment of Pediatrics (Genetics), University of Minnesota, Minneapolis, MN, USAen
dc.identifier.affiliationDepartment of Biomedicine, Aarhus University, DK-8000, Aarhus C, Denmarken
dc.identifier.affiliationPediatric Neurology, Neurogenetics and Neurobiology Unit and Laboratories, Meyer Children's Hospital, University of Florence, Florence, Italyen
dc.identifier.affiliationAustin Healthen
dc.identifier.doi10.1093/brain/awab052en
dc.type.contentTexten
dc.identifier.pubmedid33880529
local.name.researcherScheffer, Ingrid E
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptEpilepsy Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

72
checked on Nov 18, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.